Adding Sitagliptin or Pioglitazone to Type 2 Diabetes Mellitus Insufficiently Controlled With Metformin and Sulfonylurea
Launched by SUNG-CHEN LIU · Sep 2, 2010
Trial Information
Current as of June 15, 2025
Completed
Keywords
ClinConnect Summary
This is a prospective, open-label, randomized, parallel, 24-week study. Inclusion criteria: type 2 diabetes patients who were treated with stable doses of sulfonylurea and metformin to their half maximally dose (sulfonylureas \> half maximal dose, and metformin \> 1500 mg/d) for \> 10 weeks. \> 20 years old; A1C:\> 7.0 % and \< 11% Exclusion criteria: insulin use within 12 weeks of the screening visit, any contraindications for use of sitagliptin or pioglitazone, impaired renal function (serum creatinine \> 1.4 mg/dl), alanine aminotransferase (ALT) or aspartate aminotransferase levels (AST...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Type 2 diabetes patients who were treated with stable doses of sulfonylurea and metformin to their half maximally dose (sulfonylureas \> half maximal dose, and metformin \> 1500 mg/d) for \> 10 weeks
- • \> 20 years old
- • A1C: \> 7.0 % and \< 11%
- Exclusion Criteria:
- • Insulin use within 12 weeks of the screening visit
- • Any contraindications for use of sitagliptin or pioglitazone, impaired renal function (serum creatinine \> 1.4 mg/dl), alanine aminotransferase or aspartate aminotransferase levels \> 2.5 times the upper limit of normal
- • Current or prepare to pregnancy and lactation
About Sung Chen Liu
Sung-Chen Liu is a dedicated clinical trial sponsor committed to advancing medical research and improving patient outcomes through innovative study designs and rigorous trial management. With a focus on therapeutic areas such as oncology, neurology, and cardiovascular health, Liu leverages a wealth of expertise in clinical operations and regulatory compliance to ensure the highest standards of safety and efficacy in research. By fostering collaboration among stakeholders and promoting ethical practices, Sung-Chen Liu aims to drive the development of groundbreaking therapies that address unmet medical needs and enhance the quality of life for patients worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Taipei, , Taiwan
Patients applied
Trial Officials
Sung-Chen Liu, MD
Principal Investigator
Division of Endocrinology and Metabolism, Department of Internal Medicine, Mackay Memorial Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials